Canadian start-up Chinook Therapeutics Inc., which revealed a $65m series A venture capital round on 22 August, intends to capitalize on new biological insights and a favorable regulatory environment in kidney diseases to develop novel precision medicines. The company plans to take a portfolio of compounds into the clinic by 2021.
Vancouver-based Chinook will begin its discovery and development of kidney disease therapies against novel targets by focusing on rare, severe diseases, but the company acknowledges that
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?